利用miR-33b抑制物质的动脉瘤的预防或治疗
By using miR-33b inhibitors, especially antisense oligonucleotides, to reduce miR-33b levels and inhibit the expression of MMP-9, MCP-1, and JNK1, the problem of existing drugs being unable to inhibit aortic aneurysm progression has been solved, achieving effective prevention and treatment of aneurysms.
CN116096420BActive Publication Date: 2026-07-17KYOTO UNIV +3
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- KYOTO UNIV
- Filing Date
- 2021-03-02
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Existing drugs are unable to effectively inhibit the progression of aortic aneurysms, which may lead to rupture of the fragile arterial walls, and the efficacy of miR-33b inhibitors in the treatment of aneurysms is unclear in the current technology.
Method used
By using miR-33b inhibitors, especially antisense oligonucleotides, the expression of MMP-9, MCP-1, and JNK1 can be inhibited by reducing miR-33b levels, thereby preventing the formation and expansion of aneurysms.
Benefits of technology
It effectively inhibits the occurrence and expansion of aneurysms, reduces the risk of rupture, and enhances the stability of the arterial wall by lowering miR-33b levels.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN116096420B_ABST
Abstract
本发明涉及一种动脉瘤的预防或治疗剂，其将miR‑33b抑制物质、优选针对miR‑33b的反义寡核苷酸作为有效成分。
Need to check novelty before this filing date? Find Prior Art